996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Sanofi files suit in the US to defend its patent rights on Lantus

cphi-onlineAugust 11, 2017

Tag: Sanofi , Lantus , Merck Sharp & Dohme Corp. , patent infringement suit

Sanofi has filed a patent infringement suit to claim two patent rights against Merck Sharp & Dohme Corp. (on 8 August 2017) in the US District Court for the District of New Jersey.

The company claims rights of two patents.

The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product.

Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus and Lantus SoloStar products.

Previous:Addressing the safety and risk management needs of small and medium sized businesses

Next:Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service